Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart

What Was Tested

Researchers studied Insulin Aspart and Insulin Lispro in this randomized controlled trial publication.

This study provides clinical information regarding the use of insulin lispro versus insulin aspart in continuous subcutaneous insulin infusion (CSII) in adult patients with type 2 diabetes mellitus (T2D).

Who Took Part

The study group was 122 subjects.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

After a 2-week lead-in period, 122 subjects treated with CSII therapy were randomized to 32 weeks of treatment during 2 separate 16-week treatment periods (TPs) with crossover beginning with insulin lispro (n = 60) or insulin aspart (n = 62).

Adverse events (AEs) and hypoglycemic events (overall, documented symptomatic, nocturnal, or severe) were recorded throughout the TPs.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

In the crossover set-up each of the subjects took both Insulin Aspart and the comparison in turn, acting as their own control.

The methods mention a period of 2 weeks.

Data were analyzed using statistical methods that accounted for repeated measurements.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Aspart, Insulin Infusion Systems and Insulin Lispro.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Aspart and Insulin Lispro in 122 subjects over 2 weeks.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page, all human trials.